Improvement in risk prediction is important, but if it were the main aim, it would be much easier, quicker, and cheaper to ask patients about their lifetime socioeconomic circumstances, which, like CRP, generally predict CHD mortality rates even after adjustment for a wide range of conventional risk factors (9). Established approaches reduce CHD risk by the same proportion regardless of which combination of risk factors generated the risk. For example, through their influence on cholesterol levels, statins lower CHD risk to about the same relative extent independent of age, sex, presence of established CHD, baseline cholesterol level, blood pressure, or history of diabetes (10). People who experience the greatest absolute risk reduction are those at the highest level of CHD risk (7). Identifying a patient at high risk by using inexpensive methods, such as asking about general ill health (8), family history, or socioeconomic position (9), all of which are strong predictors of CHD risk, will enable the physician to target treatment to people who will experience the most benefit and therefore the most favorable ratio of benefit to side effects. If the use of such simple measures can perform this classificatory task as well as CRP measurement can, then the advantages of including CRP in risk assessment are far from clear.